Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Suzhou Basecare Medical Corporation Limited
蘇州貝康醫療股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2170)

VOLUNTARY ANNOUNCEMENT
NMPA APPROVAL OF MEDICAL DEVICE REGISTRATION CERTIFICATES FOR FERTILISATION MEDIUM AND BLASTOCYST MEDIUM

This announcement is made by Suzhou Basecare Medical Corporation Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board of directors (the "**Board**") of the Company is pleased to announce that on April 2, 2026, the Company obtained the Class III medical device registration certificates for two core medium products of Gems series of the Company, fertilisation medium and blastocyst medium (registration certificate No.: Guo Xie Zhu Jin 20263180127 and Guo Xie Zhu Jin 20263180125) from the National Medical Products Administration (the "**NMPA**").

The fertilisation and blastocyst medium approved this time, together with the Geri Medium approved in February of this year and the embryo processing fluid approved in 2025, collectively form the Gems full-line medium matrix covering the entire process from "fertilisation → cleavage-stage embryo culturing → blastocyst culturing". The fertilisation medium is specifically designed to provide an optimal environment for oocytes and sperms to facilitate fertilisation. The blastocyst medium is suitable for culturing embryos from the day 3 cleavage stage to the day 5–6 blastocyst stage; it contains multiple amino acids and vitamin B12 to provide richer nutritional support for late-stage embryonic development. Geri is the world's only wet-type, full-time-lapse culture system, with over 1,000 units installed globally. It enables 24-hour uninterrupted monitoring without interfering with embryo development. Once Geri incubator is loaded with Gems medium, its "Triple Antioxidant Protection System" can effectively address oxidative stress in aging embryos, significantly streamline laboratory procedures and ensure a stable culture environment. Internationally validated clinical studies demonstrate that this combination can significantly improve high-quality blastocyst rates and clinical pregnancy rates.

This approval marks the Company as one of the very few assisted reproductive media companies in the world to have simultaneously obtained four major internationally authoritative certifications, namely FDA (The United States Food and Drug Administration), CE (Conformité Européenne), TGA (The Therapeutic Goods Administration of Australia), and NMPA. The Chinese assisted reproduction market has welcomed its first domestic brand offering a full range of medium backed by large-scale international clinical trial data. This brand not only delivers top-tier performance comparable to leading international brands, but also leverages localized supply and solid clinical evidence to reshape the standards of China's assisted reproduction industry.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Suzhou Basecare Medical Corporation Limited
Dr. Liang Bo
Chairman and General Manager

Suzhou, PRC, April 7, 2026

As at the date of this announcement, the Board comprises Dr. LIANG Bo, Mr. KONG Lingyin and Ms. JIANG Junchao as executive Directors; Mr. ZHAO Ye and Mr. WANG Weipeng as non-executive Directors; and Dr. KANG Xixiong, Mr. LAM Siu Wing and Dr. YEUNG Shu Biu William as independent non-executive Directors.